12 mg 与 6 mg 地塞米松对 COVID-19 合并严重低氧血症成人无生命支持存活天数的影响:COVID STEROID 2 随机试验
该多中心随机临床试验于 2020 年 8 月至 2021 年 5 月在欧洲和印度 26 家医院纳入 1000 例确诊 COVID-19 且需至少 10 L/min 氧疗或机械通气的成人,1:1 随机接受 12 mg/d(n=503)或 6 mg/d(n=497)静脉地塞米松,最长 10 天。28 天死亡率 27.1% vs 32.3%(调整 RR 0.86,99%CI 0.68-1.08),90 天死亡率 32.0% vs 37.7%(调整 RR 0.87,99%CI 0.70-1.07),严重不良反应 11.3% vs 13.4%(调整 RR 0.83,99%CI 0.54-1.29)。结论提示 12 mg/d 较 6 mg/d 未显著改善主要终点,但试验可能把握度不足。
要点
- 适用人群为确诊 COVID-19 且需至少 10 L/min 氧疗或机械通气的成人,12 mg/d 与 6 mg/d 静脉地塞米松最长 10 天的主要终点无显著差异。
- 28 天死亡率 27.1% vs 32.3%(调整 RR 0.86,99%CI 0.68-1.08);90 天死亡率 32.0% vs 37.7%(调整 RR 0.87,99%CI 0.70-1.07),均无显著差异。
- 严重不良反应(包括感染性休克和侵袭性真菌感染)12 mg 组 11.3% vs 6 mg 组 13.4%(调整 RR 0.83,99%CI 0.54-1.29)。
- 原文结论指出试验可能把握度不足,不能据此推荐在严重低氧血症 COVID-19 患者中常规使用 12 mg/d 替代 6 mg/d。
适用人群与场景
- 确诊 COVID-19 且需要至少 10 L/min 氧疗或机械通气的成人,来自欧洲和印度 26 家医院。
- 随机分组 1000 例,主要终点数据可分析 971 例(12 mg 组 491 例,6 mg 组 480 例);中位年龄 65 岁(IQR 55-73),女性 305 例(31%)。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 12 mg/d 静脉地塞米松(n=503)或 6 mg/d 静脉地塞米松(n=497),最长 10 天,1:1 随机分组。
- 主要终点为 28 天内无生命支持(有创机械通气、循环支持或肾脏替代治疗)存活天数,按分层变量调整。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 多中心随机临床试验,26 家医院,纳入 1000 例确诊 COVID-19 需至少 10 L/min 氧疗或机械通气的成人,1:1 随机接受 12 mg/d 或 6 mg/d 静脉地塞米松最长 10 天。
- 28 天死亡率 27.1% vs 32.3%(调整 RR 0.86,99%CI 0.68-1.08);90 天死亡率 32.0% vs 37.7%(调整 RR 0.87,99%CI 0.70-1.07)。
- 严重不良反应(包括感染性休克和侵袭性真菌感染)11.3% vs 13.4%(调整 RR 0.83,99%CI 0.54-1.29)。
- 其他预先设定的次要终点:90 天内无生命支持存活天数、90 天内院外存活天数,原文未给出具体数值。
证据类型、等级与局限
- 证据类型:多中心随机临床试验(RCT),注册号 NCT04509973 和 CTRI/2020/10/028731。
- 原文结论指出试验可能把握度不足以识别显著差异;原文未给出证据等级或推荐强度。
- 局限:原文提及可能把握度不足;设计为多中心、随机、1:1 分组,未提及盲法。
对床旁实践的改变
- 对于确诊 COVID-19 且需至少 10 L/min 氧疗或机械通气的成人,12 mg/d 静脉地塞米松较 6 mg/d 未显著增加 28 天内无生命支持存活天数,不能据此常规将 6 mg/d 替换为 12 mg/d。
- 原文结论提示试验可能把握度不足,临床决策时应结合个体情况,不将本试验结果外推为 12 mg/d 的明确获益或危害。
指南或共识出处
- 原文未提及指南或共识出处;试验注册:ClinicalTrials.gov Identifier: NCT04509973 和 ctri.nic.in Identifier: CTRI/2020/10/028731。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: A daily dose with 6 mg of dexamethasone is recommended for up to 10 days in patients with severe and critical COVID-19, but a higher dose may benefit those with more severe disease.
OBJECTIVE: To assess the effects of 12 mg/d vs 6 mg/d of dexamethasone in patients with COVID-19 and severe hypoxemia.
DESIGN, SETTING, AND PARTICIPANTS: A multicenter, randomized clinical trial was conducted between August 2020 and May 2021 at 26 hospitals in Europe and India and included 1000 adults with confirmed COVID-19 requiring at least 10 L/min of oxygen or mechanical ventilation. End of 90-day follow-up was on August 19, 2021.
INTERVENTIONS: Patients were randomized 1:1 to 12 mg/d of intravenous dexamethasone (n = 503) or 6 mg/d of intravenous dexamethasone (n = 497) for up to 10 days.
MAIN OUTCOMES AND MEASURES: The primary outcome was the number of days alive without life support (invasive mechanical ventilation, circulatory support, or kidney replacement therapy) at 28 days and was adjusted for stratification variables. Of the 8 prespecified secondary outcomes, 5 are included in this analysis (the number of days alive without life support at 90 days, the number of days alive out of the hospital at 90 days, mortality at 28 days and at 90 days, and ≥1 serious adverse reactions at 28 days).
RESULTS: Of the 1000 randomized patients, 982 were included (median age, 65 [IQR, 55-73] years; 305 [31%] women) and primary outcome data were available for 971 (491 in the 12 mg of dexamethasone group and 480 in the 6 mg of dexamethasone group). The median number of days alive without life support was 22.0 days (IQR, 6.0-28.0 days) in the 12 mg of dexamethasone group and 20.5 days (IQR, 4.0-28.0 days) in the 6 mg of dexamethasone group (adjusted mean difference, 1.3 days [95% CI, 0-2.6 days]; P = .07). Mortality at 28 days was 27.1% in the 12 mg of dexamethasone group vs 32.3% in the 6 mg of dexamethasone group (adjusted relative risk, 0.86 [99% CI, 0.68-1.08]). Mortality at 90 days was 32.0% in the 12 mg of dexamethasone group vs 37.7% in the 6 mg of dexamethasone group (adjusted relative risk, 0.87 [99% CI, 0.70-1.07]). Serious adverse reactions, including septic shock and invasive fungal infections, occurred in 11.3% in the 12 mg of dexamethasone group vs 13.4% in the 6 mg of dexamethasone group (adjusted relative risk, 0.83 [99% CI, 0.54-1.29]).
CONCLUSIONS AND RELEVANCE: Among patients with COVID-19 and severe hypoxemia, 12 mg/d of dexamethasone compared with 6 mg/d of dexamethasone did not result in statistically significantly more days alive without life support at 28 days. However, the trial may have been underpowered to identify a significant difference.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04509973 and ctri.nic.in Identifier: CTRI/2020/10/028731.
参考来源
- Munch MW, Myatra SN, Vijayaraghavan BKT, et al. Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial. JAMA. 2021. PMID: 34673895. doi:10.1001/jama.2021.18295
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。